Menarini and Georgiamune sign deal for oral immunotherapy
The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, have announced an exclusive worldwide license and collaboration agreement with Georgiamune for GIM-621. GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumours. It is one… Read More